Ilya Pharma AB

Developing off-the-shelf immunotherapies

to treat wounds in skin and mucosa


Ilya Pharma

Ilya Pharma, being a clinical stage biopharmaceutical development company is currently pursuing three projects with drug candidates from its proprietary ILP-technology platform to clinical proof of concept and validation.



Drug Development

Well known, but instable, human therapeutic proteins are produced at the actual wound site by live lactic acid bacteria acting as mini-bioreactors. This provides a new and cost-effective way to deliver biological drugs and enables use of a wide range of proteins, not suited to be developed as biologics. 

The drug candidates are classified as ATMP and gene therapies by the EMA and FDA and the projects are fully compliant.



The innovation stems from cutting edge medical research in immunophysiology and applied microbiology at Uppsala University and the Swedish University of Agricultural Sciences. The treatments target the function of tissue-resident immune cells. The mechanism of action for the  first project of accelerated healing in skin wounds was published in PNAS 2018.


Clinical development

Unmet clinical needs targeted are treatment of wounds in skin and mucosa.

For the lead candidate ILP100 in a topical formulation, a first-in-human clinical trial (WHILYAS1, EudraCT No. 2019000680-24) have been successfully completed Q4 2020. With this milestone the Company have significantly de-risked the projects in regulatory, CMC and clinical for ILP-drug candidates.

The clinical phase II program have been outlined in pre-submissionmeetings with FDA and national regulators in Europe. A phase IIa study (WHILYAS2) in patients with diabetes and chronic wounds, funded by the EIC Accelerator is planned with first dosing in Q2 2021.  

For wound healing, the objectives are to deliver clinical value by providing cost efficient biological treatments substantially cheaper than traditional biologicals and with better efficacy than medical devices. 

For treatment of active relapse in inflammatory bowel disease the, majority of patients are not responding to treatment with the available biologics. The company are currently performing IND-enabling studies and expect to be able to enter clinical testing in 18-24 months.  



Ilya Pharma is today financed by a mix of grants and private funding. The company received a H2020 SME Instrument phase II grant 2018 of 3 MEUR and EIC Accelerator 2020 of 5.3 MEUR. The company is currently raising for the continued clinical development in phase IIs and IND enabling studies in IBD from suitable investors and potential partners with proven track record in cell- and gene therapy and therapeutics. 



Core Team

Evelina Vågesjö


Mia Phillipson


Peter Frank


Ingemar Kihlström

Chairman of the Board

Andreas Fasth

Head of Clinical Developments

Lovisa Ringstad

Head of CMC

Stefan Roos


Margareta Jorvid

Head of Regulatory Affairs

Oskar Lund




Contact Us

Ilya Pharma AB, Uppsala, Sweden

Evelina Vågesjö, CEO
+46 (0)70 636 64 94